Last reviewed · How we verify

Aerosolized Tobramycin or Vancomycin

Wright State University · FDA-approved active Small molecule

Aerosolized Tobramycin or Vancomycin is a Aminoglycoside antibiotic (tobramycin) / Glycopeptide antibiotic (vancomycin) Small molecule drug developed by Wright State University. It is currently FDA-approved for Chronic Pseudomonas aeruginosa respiratory infection in cystic fibrosis patients, Chronic respiratory infections in non-cystic fibrosis bronchiectasis. Also known as: Tobi, Tobrex; Vancocin.

Aerosolized aminoglycoside or glycopeptide antibiotics are inhaled directly into the lungs to achieve high local concentrations that kill susceptible bacteria in respiratory infections.

Aerosolized aminoglycoside or glycopeptide antibiotics are inhaled directly into the lungs to achieve high local concentrations that kill susceptible bacteria in respiratory infections. Used for Chronic Pseudomonas aeruginosa respiratory infection in cystic fibrosis patients, Chronic respiratory infections in non-cystic fibrosis bronchiectasis.

At a glance

Generic nameAerosolized Tobramycin or Vancomycin
Also known asTobi, Tobrex; Vancocin
SponsorWright State University
Drug classAminoglycoside antibiotic (tobramycin) / Glycopeptide antibiotic (vancomycin)
TargetBacterial 30S ribosomal subunit (tobramycin) / Bacterial cell wall peptidoglycan (vancomycin)
ModalitySmall molecule
Therapeutic areaInfectious Disease / Pulmonology
PhaseFDA-approved

Mechanism of action

Tobramycin and vancomycin are broad-spectrum antibiotics that inhibit bacterial protein synthesis (tobramycin) or cell wall synthesis (vancomycin). When aerosolized, they bypass systemic absorption and deliver high drug concentrations directly to infected lung tissue, particularly useful for chronic respiratory infections in cystic fibrosis and other conditions where systemic dosing may be limited by toxicity or poor lung penetration.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Aerosolized Tobramycin or Vancomycin

What is Aerosolized Tobramycin or Vancomycin?

Aerosolized Tobramycin or Vancomycin is a Aminoglycoside antibiotic (tobramycin) / Glycopeptide antibiotic (vancomycin) drug developed by Wright State University, indicated for Chronic Pseudomonas aeruginosa respiratory infection in cystic fibrosis patients, Chronic respiratory infections in non-cystic fibrosis bronchiectasis.

How does Aerosolized Tobramycin or Vancomycin work?

Aerosolized aminoglycoside or glycopeptide antibiotics are inhaled directly into the lungs to achieve high local concentrations that kill susceptible bacteria in respiratory infections.

What is Aerosolized Tobramycin or Vancomycin used for?

Aerosolized Tobramycin or Vancomycin is indicated for Chronic Pseudomonas aeruginosa respiratory infection in cystic fibrosis patients, Chronic respiratory infections in non-cystic fibrosis bronchiectasis.

Who makes Aerosolized Tobramycin or Vancomycin?

Aerosolized Tobramycin or Vancomycin is developed and marketed by Wright State University (see full Wright State University pipeline at /company/wright-state-university).

Is Aerosolized Tobramycin or Vancomycin also known as anything else?

Aerosolized Tobramycin or Vancomycin is also known as Tobi, Tobrex; Vancocin.

What drug class is Aerosolized Tobramycin or Vancomycin in?

Aerosolized Tobramycin or Vancomycin belongs to the Aminoglycoside antibiotic (tobramycin) / Glycopeptide antibiotic (vancomycin) class. See all Aminoglycoside antibiotic (tobramycin) / Glycopeptide antibiotic (vancomycin) drugs at /class/aminoglycoside-antibiotic-tobramycin-glycopeptide-antibiotic-vancomycin.

What development phase is Aerosolized Tobramycin or Vancomycin in?

Aerosolized Tobramycin or Vancomycin is FDA-approved (marketed).

What are the side effects of Aerosolized Tobramycin or Vancomycin?

Common side effects of Aerosolized Tobramycin or Vancomycin include Bronchospasm, Cough, Wheezing, Voice hoarseness, Tinnitus (tobramycin).

What does Aerosolized Tobramycin or Vancomycin target?

Aerosolized Tobramycin or Vancomycin targets Bacterial 30S ribosomal subunit (tobramycin) / Bacterial cell wall peptidoglycan (vancomycin) and is a Aminoglycoside antibiotic (tobramycin) / Glycopeptide antibiotic (vancomycin).

Related